HK1211581A1 - 新的磷酸二酯酶 型的抑制劑化合物 - Google Patents

新的磷酸二酯酶 型的抑制劑化合物

Info

Publication number
HK1211581A1
HK1211581A1 HK15112371.7A HK15112371A HK1211581A1 HK 1211581 A1 HK1211581 A1 HK 1211581A1 HK 15112371 A HK15112371 A HK 15112371A HK 1211581 A1 HK1211581 A1 HK 1211581A1
Authority
HK
Hong Kong
Prior art keywords
inhibitor compounds
phosphodiesterase type
novel inhibitor
novel
phosphodiesterase
Prior art date
Application number
HK15112371.7A
Other languages
English (en)
Inventor
Herv Geneste
Sean Turner
Michael Ochse
Karla Drescher
Lawence A Black
Katja Jantos
Clarissa Jakob
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of HK1211581A1 publication Critical patent/HK1211581A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK15112371.7A 2012-11-26 2015-12-16 新的磷酸二酯酶 型的抑制劑化合物 HK1211581A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261729877P 2012-11-26 2012-11-26
PCT/EP2013/074532 WO2014079995A2 (en) 2012-11-26 2013-11-25 Novel inhibitor compounds of phosphodiesterase type 10a

Publications (1)

Publication Number Publication Date
HK1211581A1 true HK1211581A1 (zh) 2016-05-27

Family

ID=49681010

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112371.7A HK1211581A1 (zh) 2012-11-26 2015-12-16 新的磷酸二酯酶 型的抑制劑化合物

Country Status (16)

Country Link
US (2) US9790203B2 (zh)
EP (1) EP2922842B1 (zh)
JP (1) JP2016500091A (zh)
KR (1) KR20150088873A (zh)
CN (1) CN104995183B (zh)
AU (1) AU2013349671B2 (zh)
BR (1) BR112015012156A2 (zh)
CA (1) CA2891995A1 (zh)
ES (1) ES2639956T3 (zh)
HK (1) HK1211581A1 (zh)
IL (1) IL238739A0 (zh)
MX (1) MX2015006539A (zh)
RU (1) RU2015125306A (zh)
SG (1) SG11201504115XA (zh)
TW (1) TW201422604A (zh)
WO (1) WO2014079995A2 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020086562A1 (en) * 2018-10-22 2020-04-30 Trustees Of Boston University Compositions and methods for inhibiting viral infection
GB202002926D0 (en) 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0737193A1 (en) * 1993-12-29 1996-10-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyridine adenosine antagonists
EP1104758B1 (en) * 1999-12-03 2003-07-23 Pfizer Products Inc. Acetylene derivatives as anti-inflammatory/analgesic agents
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
US20030166476A1 (en) 2002-01-31 2003-09-04 Winemiller Mark D. Lubricating oil compositions with improved friction properties
US20070032404A1 (en) 2003-07-31 2007-02-08 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
EP1755611A1 (en) 2004-06-07 2007-02-28 Pfizer Products Inc. Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
MX2007002592A (es) 2004-09-03 2007-10-10 Memory Pharm Corp Derivados 4,6 -dialcoxi - cinnolina 4 - sustituidos como inhibidores de la fosfodiesterasa 10 para el tratamiento de sindromes psiquiatricos o neurologicos.
NZ555737A (en) 2005-01-07 2010-01-29 Pfizer Prod Inc Heteroaromatic quinoline compounds and their use as PDE10 inhibitors
US20070093515A1 (en) 2005-08-16 2007-04-26 Arrington Mark P Phosphodiesterase 10 inhibitors
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
WO2007082546A1 (en) 2006-01-20 2007-07-26 H. Lundbeck A/S Use of tofisopam as a pde10a inhibitor
JP2009524637A (ja) 2006-01-27 2009-07-02 ファイザー・プロダクツ・インク アミノフタラジン誘導体化合物
CA2643983A1 (en) 2006-02-21 2007-08-30 Amgen, Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
JP2009527560A (ja) 2006-02-21 2009-07-30 アムゲン インコーポレイティッド ホスホジエステラーゼ１０阻害剤としてのシンノリン誘導体
WO2007096743A1 (en) 2006-02-23 2007-08-30 Pfizer Products Inc. Substituted quinazolines as pde10 inhibitors
WO2007100880A1 (en) 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
US20070265258A1 (en) 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
EP1996574A1 (en) 2006-03-08 2008-12-03 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
CA2654394A1 (en) 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
CN101495476A (zh) 2006-07-10 2009-07-29 H.隆德贝克有限公司 6,7-二烷氧基喹唑啉、6,7-二烷氧基酞嗪和6,7-二烷氧基异喹啉的(3-芳基-哌嗪-1-基)、(2-芳基-吗啉-4-基)和(2-芳基-硫代吗啉-4-基)衍生物
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
WO2009025823A1 (en) 2007-08-21 2009-02-26 Amgen Inc. Phosphodiesterase 10 inhibitors
US20090062291A1 (en) 2007-08-22 2009-03-05 Essa Hu Phosphodiesterase 10 inhibitors
WO2009029214A1 (en) 2007-08-23 2009-03-05 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
TW200918519A (en) 2007-09-19 2009-05-01 Lundbeck & Co As H Cyanoisoquinoline
AU2008329775A1 (en) 2007-11-30 2009-06-04 Biotie Therapies Gmbh Aryl and heteroaryl fused imidazo[1,5-a]pyrazines as inhibitors of phosphodiesterase 10
WO2009068246A2 (en) 2007-11-30 2009-06-04 Elbion Gmbh Methods of treating obesity and metabolic disorders
EP2227472A1 (en) 2007-11-30 2010-09-15 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
US20090143361A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
JP2010070514A (ja) * 2008-09-19 2010-04-02 Toray Ind Inc ピラゾール誘導体及びその医薬用途
WO2010054260A1 (en) 2008-11-07 2010-05-14 Biotie Therapies Gmbh Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
WO2011008597A1 (en) 2009-07-14 2011-01-20 Schering Corporation Dihydroimidazoisoquinoline derivatives useful as pde10 inhibitors
CA2776240C (en) 2009-10-30 2017-06-13 Janssen Pharmaceutica Nv Radiolabelled pde10 ligands
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物
KR101199229B1 (ko) * 2010-06-18 2012-11-08 주식회사 알파켐 플루오란센 유도체 및 이를 이용한 유기전계발광소자
JP5820887B2 (ja) 2010-11-10 2015-11-24 ハー・ルンドベック・アクチエゼルスカベット 放射性標識されたフェニルイミダゾールベースのリガンド
US8691821B2 (en) 2010-11-11 2014-04-08 Bristol-Myers Squibb Company Oxazolidinones as modulators of mGluR5
US20120214842A1 (en) 2011-02-18 2012-08-23 Exonhit Therapeutics Sa Methods for treating diseases of the retina
CN103159738B (zh) 2011-12-19 2016-09-07 上海泓博智源医药股份有限公司 炔基桥连的杂芳香化合物及其应用

Also Published As

Publication number Publication date
MX2015006539A (es) 2015-10-30
WO2014079995A2 (en) 2014-05-30
EP2922842B1 (en) 2017-06-14
JP2016500091A (ja) 2016-01-07
AU2013349671B2 (en) 2018-03-29
ES2639956T3 (es) 2017-10-30
RU2015125306A (ru) 2017-01-10
AU2013349671A1 (en) 2015-05-21
US9790203B2 (en) 2017-10-17
CN104995183B (zh) 2018-04-06
BR112015012156A2 (pt) 2017-07-11
TW201422604A (zh) 2014-06-16
US20140148461A1 (en) 2014-05-29
IL238739A0 (en) 2015-06-30
EP2922842A2 (en) 2015-09-30
CN104995183A (zh) 2015-10-21
SG11201504115XA (en) 2015-07-30
KR20150088873A (ko) 2015-08-03
WO2014079995A3 (en) 2014-07-17
US20180030033A1 (en) 2018-02-01
CA2891995A1 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
IL263262B (en) Atr kinase inhibitor compounds, preparations containing them, their uses and methods for their preparation
SG10201605196PA (en) Novel Inhibitor Compounds Of Phosphodiesterase Type 10A
HK1215253A1 (zh) 作為激酶抑制劑的吡咯並嘧啶化合物
HK1201519A1 (zh) 磷酸二酯酶第 型的抑制劑
HK1211921A1 (zh) 抑制劑化合物
HK1211942A1 (zh) 作為激酶抑制劑的吡唑並嘧啶化合物
HK1210178A1 (zh) 作為 抑制劑的取代吡啶並吡嗪類化合物
HK1219273A1 (zh) 磷酸二酯酶 型的新型抑制劑化合物
HK1211024A1 (zh) 的抑制劑
HK1206728A1 (zh) 型磷酸二酯酶之新型抑制劑化合物
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
GB201211019D0 (en) Inhibitor compounds
HK1211581A1 (zh) 新的磷酸二酯酶 型的抑制劑化合物
PT2784068E (pt) Inibidor da fosfodiesterase-4 capaz de evitar os vómitos
HK1211284A1 (zh) 磷酸二酯酶 型的抑制劑化合物